AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9691834 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized patients
Number of subjects: 164
Study 9691834 — intervention group
Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 164
Study 7640140 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.1 micrograms min-1)
Number of subjects: 19
Study 7640140 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 19
Study 7640140 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 19
Study 7640140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7640140 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler sonography
Number of subjects: 19
Study 2475323 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid meperidine (150 mg, p.o.)
Number of subjects: 20
Study 2475323 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant imipramine (100 mg, p.o.)
Number of subjects: 20
Study 2475323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 780063 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg oxprenolol daily
Number of subjects: 32
Study 780063 — intervention group
Group type: COMPARATOR
Intervention: 4 mg diazepam daily
Number of subjects: 32
Study 30759132 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine
Number of subjects: 100
Study 30759132 — intervention group
Group type: COMPARATOR
Intervention: Vi-PS vaccine
Number of subjects: 100
Study 27161285 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations containing Cichorium intybus root extract with UV filters
Number of subjects: 50
Study 27161285 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations containing Cichorium intybus root extract without UV filters
Number of subjects: 50
Study 27161285 — intervention group
Group type: COMPARATOR
Intervention: Vehicle formulations containing UV filters
Number of subjects: 50
Study 27161285 — intervention group
Group type: COMPARATOR
Intervention: Vehicle formulations without UV filters
Number of subjects: 50
Study 25626920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (1 mg/mL) for three consecutive months
Number of subjects: 26
Study 25626920 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (10 mg/mL) for three consecutive months
Number of subjects: 26
Study 25626920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (1 mg/mL)
Number of subjects: 26
Study 25626920 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (10 mg/mL)
Number of subjects: 26
Study 23298693 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive music intervention
Number of subjects: 39
Study 23298693 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive music intervention
Number of subjects: 39
Study 23298693 — intervention group
Group type: COMPARATOR
Intervention: No-music control
Number of subjects: 39
Study 21546927 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein breakfast (NP; 18 ± 1 g protein)
Number of subjects: 10
Study 21546927 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein breakfast (HP; 50 ± 1 g protein)
Number of subjects: 10
Study 21546927 — intervention group
Group type: COMPARATOR
Intervention: Breakfast consumption (both NP and HP)
Number of subjects: 10
Study 20396724 — intervention group
Group type: EXPERIMENTAL
Intervention: Poetam and anaferon (pediatric formulation) administered in combination with iron preparation
Number of subjects: 0
Study 17520399 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ondansetron
Number of subjects: 0
Study 17520399 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron
Number of subjects: 0
Study 15506584 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 226
Study 15506584 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 226
Study 11451697 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg orally once daily
Number of subjects: 410
Study 11451697 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg orally once daily
Number of subjects: 410
Study 10052247 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 80 mg/m2 day 1-3, folinic acid 100 mg/m2 day 1-3, 5-fluorouracil 340 mg/m2 day 1-3, and epirubicin 60 mg/m2 day 1, repeated every three weeks
Number of subjects: 23
Study 7746030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 281
Study 7746030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 30646302 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cannabis
Number of subjects: 0
Study 30646302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis
Number of subjects: 0
Study 26857383 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring with health coaching telephone calls and telemonitoring.
Number of subjects: 1437
Study 26857383 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1437
Study 24444280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus desmopressin (0.3 μg/kg)
Number of subjects: 21
Study 24444280 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor alone
Number of subjects: 21
Study 24444280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus desmopressin
Number of subjects: 21
Study 22776554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Internet and mobile phone based intervention
Number of subjects: 0
Study 22776554 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard cardiac rehabilitation without tailored intervention)
Number of subjects: 0
Study 20510459 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER
Number of subjects: 258
Study 20510459 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 258
Study 18789008 — intervention group
Group type: EXPERIMENTAL
Intervention: ronkoleukin
Number of subjects: 33
Study 17274312 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 treatment at 2.2 bar
Number of subjects: 360
Study 17274312 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 treatment at 2.5 bar
Number of subjects: 360
Study 17274312 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 treatment (both protocols)
Number of subjects: 360
Study 17274312 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 treatment with positive expectation
Number of subjects: 360
Study 17274312 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 treatment with indifferent expectation
Number of subjects: 360
Study 17274312 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 treatment with negative expectation
Number of subjects: 360
Study 12599053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus monkey rotavirus-based quadrivalent vaccine (4 x 10^5 plaque-forming units/dose)
Number of subjects: 2207
Study 12599053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus monkey rotavirus-based quadrivalent vaccine
Number of subjects: 2207
Study 12599053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2207
Study 10731460 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention condition (High 5 project)
Number of subjects: 28
Study 10731460 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control condition
Number of subjects: 28
Study 8841152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan
Number of subjects: 12
Study 8841152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan 1 hour before 50 mg quinidine
Number of subjects: 12
Study 8841152 — intervention group
Group type: COMPARATOR
Intervention: 50 mg quinidine
Number of subjects: 12
Study 8841152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8841152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan (poor metabolizers)
Number of subjects: 12
Study 8841152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan (extensive metabolizers with quinidine)
Number of subjects: 12
Study 8841152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan (extensive metabolizers)
Number of subjects: 12
Study 8841152 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin-induced cough frequency
Number of subjects: 12
Study 1738578 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation with naloxone (0.4 mg)
Number of subjects: 21
Study 1738578 — intervention group
Group type: COMPARATOR
Intervention: Vibratory stimulation with placebo
Number of subjects: 21
Study 1738578 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 21
Study 6732565 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior trabeculoplasty (ATM)
Number of subjects: 118
Study 6732565 — intervention group
Group type: COMPARATOR
Intervention: Posterior trabeculoplasty (PTM)
Number of subjects: 118
Study 6732565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anterior and posterior trabeculoplasty
Number of subjects: 118
Study 31103881 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial adversity risk
Number of subjects: 297
Study 31103881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair cortisol
Number of subjects: 297
Study 31103881 — intervention group
Group type: COMPARATOR
Intervention: Sociodemographic adversity risk
Number of subjects: 297
Study 30412448 — intervention group
Group type: EXPERIMENTAL
Intervention: Abicipar 1 mg
Number of subjects: 64
Study 30412448 — intervention group
Group type: EXPERIMENTAL
Intervention: Abicipar 2 mg
Number of subjects: 64
Study 30412448 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg
Number of subjects: 64
Study 27655761 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM) - 250 mL (520 kcal) consisting of rapeseed oil (440 kcal), emulsifier, sucrose, flavor cocktail
Number of subjects: 17
Study 27655761 — intervention group
Group type: COMPARATOR
Intervention: Water load (WL)
Number of subjects: 17
Study 23765873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg
Number of subjects: 102
Study 23765873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 23765873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 4 or 8 mg/kg
Number of subjects: 102
Study 22443478 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 358
Study 22443478 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 358
Study 20736125 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding 1 hour before examination (arm 1)
Number of subjects: 34
Study 20736125 — intervention group
Group type: COMPARATOR
Intervention: Feeding schedule adjusted to ensure no feeding within 2 hours before examination (arm 2)
Number of subjects: 34
Study 18509177 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes in the metastatic setting
Number of subjects: 982
Study 15950838 — intervention group
Group type: EXPERIMENTAL
Intervention: Text + pictogram labels (experimental group)
Number of subjects: 87
Study 15950838 — intervention group
Group type: COMPARATOR
Intervention: Text-only labels (control group)
Number of subjects: 87
Study 12576914 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term exercise program (18 months)
Number of subjects: 140
Study 12576914 — intervention group
Group type: COMPARATOR
Intervention: Short-term exercise program (3 months)
Number of subjects: 140
Study 11783207 — intervention group
Group type: EXPERIMENTAL
Intervention: CHM plus chemotherapy
Number of subjects: 86
Study 11783207 — intervention group
Group type: COMPARATOR
Intervention: Single chemotherapy
Number of subjects: 86
Study 8606329 — intervention group
Group type: EXPERIMENTAL
Intervention: DES-exposed individuals (253 sons and 296 daughters)
Number of subjects: 549
Study 8606329 — intervention group
Group type: COMPARATOR
Intervention: Unexposed individuals (241 men and 246 women)
Number of subjects: 549
Study 1768539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adrenaline infusions
Number of subjects: 30
Study 1768539 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine infusions
Number of subjects: 30
Study 7034858 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine pessaries for two weeks
Number of subjects: 100
Study 7034858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7034858 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine pessaries
Number of subjects: 100
Study 29858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg) plus Albendazole (400 mg)
Number of subjects: 701
Study 29858149 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg) plus Oxantel Pamoate (25 mg/kg)
Number of subjects: 701
Study 29858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg) plus Tribendimidine (200 mg or 400 mg)
Number of subjects: 701
Study 29858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg) alone
Number of subjects: 701
Study 27625133 — intervention group
Group type: EXPERIMENTAL
Intervention: Core needle biopsy (Group A)
Number of subjects: 105
Study 27625133 — intervention group
Group type: COMPARATOR
Intervention: Fine needle aspiration cytology (Group B)
Number of subjects: 105
Study 25734218 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0
Study 25734218 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 0
Study 25734218 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 0
Study 22817789 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspection during instrument insertion (3 minutes during insertion + 6 minutes during withdrawal)
Number of subjects: 100
Study 22817789 — intervention group
Group type: COMPARATOR
Intervention: Inspection during instrument withdrawal (9 minutes)
Number of subjects: 100
Study 20946233 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets with slow-release insecticides (KO Tab 123)
Number of subjects: 15254
Study 18179321 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuating or personalizing experience with an outgroup member
Number of subjects: 0
Study 16009169 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice a week for 5 weeks)
Number of subjects: 40
Study 16009169 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 40
Study 16009169 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 40
Study 12890954 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic local anesthesia with 1% lidocaine
Number of subjects: 50
Study 12890954 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 50
Study 10873672 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (400 mg/day for 5 weeks)
Number of subjects: 0
Study 10873672 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (10 and 15 weeks)
Number of subjects: 0
Study 10873672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10873672 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C supplementation (15 weeks) followed by placebo
Number of subjects: 0
Study 10873672 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from vitamin C supplementation
Number of subjects: 0
Study 9168289 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone for 24 hours
Number of subjects: 499
Study 9168289 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone for 48 hours
Number of subjects: 499
Study 9168289 — intervention group
Group type: COMPARATOR
Intervention: Tirilazad for 48 hours
Number of subjects: 499
Study 7680374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (high dose 600 mg/d and low dose 300 mg/d)
Number of subjects: 161
Study 7680374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (low dose 300 mg/d)
Number of subjects: 161
Study 3524742 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop ileostomy
Number of subjects: 47
Study 3524742 — intervention group
Group type: COMPARATOR
Intervention: Loop transverse colostomy
Number of subjects: 47
Study 30225981 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based weight loss intervention for mothers
Number of subjects: 371
Study 30225981 — intervention group
Group type: COMPARATOR
Intervention: Standard Women, Infants, Children (control)
Number of subjects: 371
Study 30225981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 371
Study 29905927 — intervention group
Group type: EXPERIMENTAL
Intervention: regorafenib-FOLFIRI
Number of subjects: 181
Study 29905927 — intervention group
Group type: COMPARATOR
Intervention: placebo-FOLFIRI
Number of subjects: 181
Study 27318866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual low-density lipoprotein cholesterol-lowering therapy (DLLT) with statin-ezetimibe combination
Number of subjects: 100
Study 27318866 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 100
Study 27318866 — intervention group
Group type: EXPERIMENTAL
Intervention: DLLT
Number of subjects: 100
Study 27318866 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 100
Study 24004695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral attention network modulation by task-irrelevant memory signals
Number of subjects: 0
Study 24004695 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom-up, stimulus-driven distraction
Number of subjects: 0
Study 24004695 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down control of attention
Number of subjects: 0
Study 24004695 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in connectivity among critical nodes of ventral and dorsal frontoparietal regions
Number of subjects: 0
Study 22181006 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.05 μg/kg/min
Number of subjects: 20
Study 22181006 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.08 μg/kg/min
Number of subjects: 20
Study 22181006 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.10 μg/kg/min
Number of subjects: 20
Study 22181006 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 20
Study 22181006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20105045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus administered 15 min before meal
Number of subjects: 30
Study 20105045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus administered just before meal
Number of subjects: 30
Study 20105045 — intervention group
Group type: COMPARATOR
Intervention: Bolus administered just after meal
Number of subjects: 30
Study 17405792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 307
Study 17405792 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 307
Study 16149831 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap procedure
Number of subjects: 97
Study 16149831 — intervention group
Group type: COMPARATOR
Intervention: Sphincter pharyngoplasty
Number of subjects: 97
Study 12151162 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 0
Study 12151162 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 0
Study 12151162 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium 550 mg
Number of subjects: 0
Study 12151162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10073326 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetrexate, leucovorin, and dapsone administered for 21 +/- 3 days; trimetrexate glucuronate, 45 mg/m2; leucovorin, 20 mg/m2; dapsone, 100 mg daily
Number of subjects: 0
Study 7658230 — intervention group
Group type: EXPERIMENTAL
Intervention: New analytic procedure requiring six plasma samples for CMRglc measurement.
Number of subjects: 0
Study 7658230 — intervention group
Group type: COMPARATOR
Intervention: Conventional method requiring 30 or more plasma samples for CMRglc measurement.
Number of subjects: 0
Study 2291659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole 0.5 g
Number of subjects: 24
Study 2291659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole 1 g
Number of subjects: 24
Study 2291659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole 2 g
Number of subjects: 24
Study 2291659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole (all doses)
Number of subjects: 24
Study 7244426 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine hydrochloride
Number of subjects: 6
Study 7244426 — intervention group
Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 6
Study 7244426 — intervention group
Group type: COMPARATOR
Intervention: Comparison of bronchospasm after saline
Number of subjects: 6
Study 31704504 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) + full-mouth ultrasonic scaling (FMUS)
Number of subjects: 30
Study 31704504 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth ultrasonic scaling (FMUS) alone
Number of subjects: 30
Study 31704504 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PDT + FMUS and FMUS alone)
Number of subjects: 30
Study 30609761 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific collagen peptides (TENDOFORTE®)
Number of subjects: 20
Study 30609761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30609761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (collagen peptides and placebo)
Number of subjects: 20
Study 28915426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8mg i.v. in 50ml normal saline
Number of subjects: 80
Study 28915426 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50ml normal saline)
Number of subjects: 80
Study 25872653 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behaviour therapy (TF-CBT)
Number of subjects: 44
Study 25872653 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 44